Accumulating evidence suggests flavonoid intake is associated with reduced risk of non-communicable diseases. We aimed to systematically determine and quantify the potential association between dietary anthocyanin intake and risk of cardiovascular diseases (CVD). A systematic literature search of studies reporting anthocyanin intake and risk of fatal or nonfatal CVD was performed using SCOPUS, MEDLINE, CINAHL and Cochrane Library. The relative risk (RR) or hazard ratio (HR) of highest category of anthocyanin foods were pooled in a random-effects meta-analysis. Subgroup analysis were conducted to determine possible sources of heterogeneity. The meta-analysis suggested intake of dietary anthocyanins and reduced risk of CHD (RR ¼ 0.91, 95% CI: 0.83, 0.99; I 2 ¼ 12.0, P h ¼ 0.337) and CVD mortality (RR ¼ 0.92, 95% CI: 0.87, 0.97; I 2 ¼ 0.0, P h ¼ 0.584). However, there was no relationship between the intake of these compounds and reduced risk of MI, stroke or total CVD. Subgroup analysis determined reduced risk of CHD and CVD mortality was more prominent for anthocyanidin intake, as opposed to anthocyanin or berries. Our systematic review and meta-analysis provides evidence that anthocyanins, specifically anthocyanidins, reduce the risk of CHD and CVD mortality. Further randomized controlled trials on anthocyanin intake and CVD risk factors are needed to support these findings.
Introduction
Historically, berry and cherry plant products have been widely utilized as medicinal sources to treat and prevent a number of ailments, including, but not limited to; stomachaches, snakebites, inflammation, fevers and pains (Hummer 2010; Stewart 2003) . More recently, there is robust epidemiological evidence that a diet rich in berry fruits is associated with a reduced risk of non-communicable and neurodegenerative diseases (Devore et al. 2012; Guo et al. 2016; Huang et al. 2016) . Such health benefits are thought to be attributable to their naturally occurring flavonoids, which are further sub-classified into flavonols, flavones, flavanones, flavan-3-ols, isoflavones, and anthocyanins (Wang et al. 2014) . Liu et al. (2017) , recently demonstrated through a dose-response meta-analysis that increased intake of dietary flavonoids was associated with reduced risk of all-cause mortality. Similarly, Wang et al. (2014) , reported flavonoid intake was associated with reduced risk of cardiovascular disease (CVD). However, individual flavonoids might not be equally associated with cardioprotection, given the extensive differences that exist between their bioavailability and bioactivity. Notably, berry fruits are rich in the subclass of flavonoids anthocyanins, which evidence suggests the bioavailability to be greater than previously estimated (Czank et al. 2013) . Anthocyanins (from the Greek anthos, a flower, and kyanos, dark blue) are important secondary plant metabolites that occur primarily as glycosides of their aglycone anthocyanidins ( Figure 1 ). They are water-soluble pigments often responsible for the orange, red, and blue colors in fruits, vegetables, flowers, and other tissues in plants (Delgado-Vargas, Jim enez, and Paredes-L opez 2000) . Hence are most abundant in commonly consumed fruits that are dark red and purple, such as blackberries, raspberries, strawberries, blueberries, red grapes and cherries (Clifford 2000; Horbowicz et al. 2008) . Accumulating evidence substantiates that anthocyanins have a putative role in overall cardiovascular health (Reis et al. 2016) .
Recent in vitro studies have established that anthocyanin metabolites are just as bioactive, if not more, than their parent compounds (Amin et al. 2015; Keane et al. 2016) . They have been demonstrated to elicit vasoprotective properties such as antioxidant, anti-inflammatory, anti-atherogenic and vasodilatory actions (Castaneda-Ovando et al. 2009; Edwards et al. 2015; Wang et al. 1999) and there is now a growing body of evidence also supports that intake of dietary anthocyanins can improve functional vascular health in vivo (Fairlie-Jones et al. 2017; Jennings et al. 2012) . The potential underlying mechanisms for the aforementioned might involve the augmentation of endothelial-derived nitric oxide (NO) bioavailability. Anthocyanins can directly increase NO through upregulation of the endothelial nitric oxide synthase and L-arginine pathways, but also indirectly by potentiating the nitrate-nitrite-NO pathway, and minimizing degradation of NO via their antioxidant actions (Edwards et al. 2015; Rocha et al. 2014) . Nitric oxide is an integral molecule in regulating endothelial homeostasis and anthocyanin-rich foods have previously been demonstrated to improve endothelial function (Rodriguez-Mateos et al. 2013) , which has been replicated in studies that supplemented with purified anthocyanins (Zhu et al. 2011) . Accordingly, in a recent attempt to evaluate the effect of flavonoid intake on mortality, subgroup analysis determined significant decreases in risk of CVD mortality associated with the highest intake of anthocyanidins (Summary relative risk ¼ 0.89, 95% CI: 0.83, 0.95) amongst 5 cohorts (Grosso et al. 2017) . However, as highlighted by these and other authors (Grosso et al. 2017; Hooper et al. 2008) , there is a need for a better understanding of the role of specific flavonoid subclasses in relation to health and disease. Moreover, there is inherent structural complexity among different flavonoids and diversity between flavonoid-containing foods and only CVD mortality was investigated (Grosso et al. 2017) . Thus, conceptually it is possible that encompassing all flavonoids resulted in missing studies that evaluated anthocyanin-rich foods and the relationship between the intake of these compounds and risk of CVD incidence has not recently been determined since Wang and colleagues (2014) previously reported significant reductions in CVD risk associated with intake of anthocyanidins (RR ¼ 0.89, 95% CI: 0.83, 0.96; I 2 ¼ 0.0, P h ¼ 0.741) in a subgroup analysis of 3 studies. Therefore, the aim of the current meta-analysis was to evaluate the quantitative relationship between dietary intake of parent anthocyanidin compounds and/or anthocyanin-rich foods and the risk of CVD and related mortality from prospective cohort studies.
Methods

Search strategy
This review followed the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines (Stroup et al. 2000) . The protocol of this systematic review was pre-registered with PROSPERO, the International Prospective Register of Systematic Reviews [registration number: CRD42018089121]. A systematic literature search was performed using SCOPUS, MEDLINE (ProQuest), CINAHL (EBSCO) and Cochrane Library from inception until January 2018. The search strategy was conducted using Medical Subject Heading (MeSH), Boolean operations and formed from existing reviews of anthocyanin-rich foods (Fairlie-Jones et al. 2017) , collated in three key concepts; (i) anthocyanins, (ii) cardiovascular disease and (iii) prospective study design. Furthermore, the reference list of retrieved systematic reviews and included studies were hand searched to find potential articles that could be included in the current meta-analysis.
Study selection
Studies were included for analysis if they met the following inclusion criteria: (1) were a prospective study in adults (18 years) including; prospective cohort, nested case-control and case-cohort studies; (2) included 2 doses of anthocyanins or anthocyanin-rich foods as exposure; (3) reported fatal or non-fatal CVD events as outcome of interest [i.e. coronary heart disease, ischemic heart disease, coronary artery disease, angina, myocardial infarction, heart failure, cerebrovascular disease (ischemic stroke and hemorrhagic stroke), peripheral artery disease, CVD mortality]; (4) reported relative risk (RR) or hazard ratio (HR) and their corresponding 95% confidence intervals (or sufficient data to compute them). Titles and abstracts were independently reviewed using Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) by two researchers (RK and GH). Only full texts that were published in English or had an existing translation were retrieved and examined.
Data extraction and quality assessment
Data was independently extracted into piloted forms by two investigators (RK and KMK) in accordance with the Metaanalysis of Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al. 2000) . Any discrepancies were resolved by reviewing the original article. The following data was extracted from each study: the first author's last name(s), publication date, location, the cohort name, participant's age (at baseline) and sex, the follow up period, the method of dietary assessment and anthocyanin exposure range, type of outcome, number of cases, HR or RR and their corresponding 95% CI and any covariate adjustments. Quality of each study was evaluated using the nine-star Newcastle-Ottawa scale (Stang 2010) , which assesses three major domains; selection of the study group (0-4 stars), comparability (0-2 stars) and outcome in the cohorts (0-3 stars). A maximum of 9stars could be awarded, where 0-3, 4-6 and 7-9 stars were regarded as low, moderate and high quality, respectively.
Statistical analysis
A random-effects meta-analysis was conducted because of unexplained heterogeneity between studies, where the common measure was RR. All included studies used COX's models, therefore HR were directly considered as RRs. The multivariate-adjusted RR and standard errors (SEs; derived from their corresponding 95% CIs) were logarithm transformed. If individual studies reported RR for multiple outcomes of CVD, or were stratified by gender, the risk estimates were pooled by fixed-effects model and the summary estimate was used in the main meta-analysis (Aune et al. 2017) .
Sensitivity analysis was performed by omitting one study at a time to evaluate the potential bias and robustness of the overall risk estimate. Heterogeneity between studies was determined by v 2 by Cochran's Q test (significance level at P h < 0.10) (DerSimonian and Laird 1986) and the I 2 statistic. For the I 2 statistic, I 2 values 25%, 50%, 75% and >75% indicated no, little, moderate and significant heterogeneity, respectively. Subgroup analysis was conducted to determine possible sources of heterogeneity. Subsequently, the effect of exposure, type of outcome, sex, location, sample size and follow-up length of the included studies evaluated. Potential publication bias was evaluated by Egger's test (P < 0.10) and visual inspection of funnel plots (Begg and Mazumdar 1994) . All statistical analysis was conducted using STATA v.15.0 (StataCorp, College Station, Texas, USA), P < 0.05 was considered significant unless otherwise stated.
Results
Literature search
The literature search and study selection results are presented in Figure 2 . There were 1689 studies initially identified by the search strategy. After exclusion of duplicates 1277 titles and abstracts were reviewed. Seventy-six full texts were retrieved and after irrelevant articles were excluded for; wrong exposure (29), wrong study design (22), wrong outcomes (5), not complete (1), not English (2); 17 articles remained. Two additional study was identified by hand searching reference lists.
Study characteristics
The characteristics of the included studies are presented in Table 1 . Nineteen studies involving 602,054 participants with more than 22,673 incidence of non-fatal or fatal CVD were included in the current meta-analysis (Cassidy et al. 2016; Cassidy et al. 2013; Cassidy et al. 2012; Goetz et al. 2016; Hirvonen et al. 2000; Hjartåker et al. 2015; Ivey et al. 2013; Jacques et al. 2015; Knekt et al. 1996; Lai et al. 2015; Larsson, Virtamo, and Wolk 2013; McCullough et al. 2012; Mink et al. 2007; Mizrahi et al. 2009; Mursu et al. 2008; Ponzo et al. 2015; Sesso et al. 2007; Tresserra-Rimbau et al. 2014; Zamora-Ros et al. 2013) . All studies were published between 1996-2016, with seven studies conducted in USA (Cassidy et al. 2016; Cassidy et al. 2013; Cassidy et al. 2012; Goetz et al. 2016; McCullough et al. 2012; Mink et al. 2007; Sesso et al. 2007 ) eleven in Europe (Hirvonen et al. 2000; Hjartåker et al. 2015; Jacques et al. 2015; Knekt et al. 1996; Lai et al. 2015; Larsson, Virtamo, and Wolk 2013; Mizrahi et al. 2009; Mursu et al. 2008; Ponzo et al. 2015; Tresserra-Rimbau et al. 2014; Zamora-Ros et al. 2013 ) and one in Australia (Ivey et al. 2013) . Five studies reported anthocyanin intake (1.9-74.6 mg/day) (Cassidy et al. 2016; Cassidy et al. 2013; Cassidy et al. 2012; Jacques et al. 2015; Tresserra-Rimbau et al. 2014) , seven studies reported anthocyanidin intake (0-41 mg/day) (Goetz et al. 2016; Ivey et al. 2013; Jacques et al. 2015; McCullough et al. 2012; Mink et al. 2007; Mursu et al. 2008; Ponzo et al. 2015; Zamora-Ros et al. 2013 ) and seven studies reported berry intake [0-365 g/day (Hirvonen et al. 2000; Knekt et al. 1996; Lai et al. 2015; Mizrahi et al. 2009 ); 0-0.5 median servings/day (Hjartåker et al. 2015; Larsson, Virtamo, and Wolk 2013; Sesso et al. 2007) ]. The follow-up length of the included studies ranged from 4.3 to 41 years. All studies provided covariate-adjusted risk models (e.g. age, sex, BMI, smoking). Quality scores were 6 stars (Table 1; supplemental), two studies were moderate quality (6 stars) (Hirvonen et al. 2000; Ivey et al. 2013 ) and all other studies considered high quality ( 7 stars).
Intake of anthocyanins and cardiovascular disease risk
The random-effects pooled results for fully adjusted risk estimates of subgroups of CVD ( Figure 3) showed an inverse association for intake of dietary anthocyanins and reduced risk of CHD (RR ¼ 0.91, 95% CI: 0.83, 0.99; I 2 ¼ 12.0, P h ¼ 0.337) and CVD mortality (RR ¼ 0.92, 95% CI: 0.87, 0.97) with no between-study heterogeneity (I 2 ¼ 0.0, P h ¼ 0.584). However, there was no relationship between the intake of these compounds and reduced risk of MI, stroke or total CVD. Subgroup analyses can be found in (Table 2 ; Supplemental). Reduced risk of CHD (RR ¼ 0.84, 95% CI: 0.71, 0.98; I 2 ¼ 31.6, P h ¼ 0.227) and CVD mortality (RR ¼ 0.92, 95% CI: 0.87, 0.97; I 2 ¼ 0.0, P h ¼ 0.491) remained significant for anthocyanidin studies only, as opposed to studies which determined intake of berries or anthocyanins. Subgroup analysis also determined risk estimates to be significant for studies conducted in the USA for both CHD (RR ¼ 0.84, 95% CI: 0.71, 0.98; I 2 ¼ 31.6, P h ¼ 0.227) and CVD mortality (RR ¼ 0.89, 95% CI: 0.83, 0.96;
Apart from a single study that suggests anthocyanidin intake reduces risk of total CVD (Ponzo et al. 2015) ; risk of MI, stroke and total CVD remained non-significant when stratified by exposure, sex, location, follow up and sample size. Stroke was further stratified by type ( Figure 4 ), but no association was found between the intake of these compounds and reduced risk of cerebral infarction, ischemic or hemmorrhagic strokes.
Publication bias and sensitivity analysis
Egger's test suggested the absence of significant publication for all studies based on each type of CVD (P 0.127). This was confirmed by visual inspection of the funnel plots (Figure 1; supplemental) which showed no substantial asymmetry. Overall, sensitivity analysis determined no materially different risk estimates indicating stable results between risk estimates of studies included in the pooled estimates (Figure 1; supplemental) .
Discussion
The current meta-analysis of nineteen prospective cohort studies is the largest, most comprehensive and contemporary to evaluate the association between dietary anthocyanin intake and risk of CVD. Our findings indicate that dietary intake of anthocyanins is inversely associated with CHD and CVD mortality (Figure 3) , which is consistent with the findings of others (Grosso et al. 2017; Wang et al. 2014) . Conversely, we found no relationship between the intake of these compounds and the risk of Stroke, MI or total CVD. This is surprising given that there is commonality in the etiology of CVDs and a recent meta-analysis of randomized controlled trial showed and berry supplementation improved risk factors of CVD; specifically lipid profiles, systolic and diastolic blood pressure, which the authors speculate might be, at least partly, attributable to the anthocyanin content (Lu ıs, Domingues, and Pereira 2018). Moreover, there is a growing body of evidence that increased flavonoid intake is associated with reduced risk of stroke (Tang et al. 2016 ) and total CVD (Wang et al. 2014) . However, most of the prior epidemiologic evidence on flavonoids and CVD risk, specifically stroke, has focused on flavanones, flavones, flavonols, and flavan-3-ols (Tang et al. 2016 ) that might have different bioactivities compared to anthocyanins. Conversely, there are a number of weaknesses in the available data. Firstly, the majority of included studies in the current meta-analysis used FFQs to assess dietary intake of berries which have previously been reported to be less reliable to assess berry intake compared to other foods (Bjelke, 1974) . Secondly, most included studies used single assessments to categorize dietary anthocyanin intake, but this could likely change during the study (Jacques et al. 2015) . Thirdly, although determination of anthocyanin/anthocyanidin intake is likely to be more comprehensive than intake of berries alone, there is the possibility of measurement error and misclassification. Furthermore, there is inherent difficulty in determining the intake of these compounds because the databases have missing foods and limited information on retention of these compounds following cooking (Zamora-Ros et al. 2011), and some studies would likely have used outdated databases. Thus, the different associations between CVDs might be confounded by suboptimal quantification of dietary intake of berries and/or anthocyanins, but could also be because of the limited number of studies found examining MI and total CVD.
In the current meta-analysis, we found higher anthocyanin intake was associated with a 9% and 8% reduced risk of CHD and CVD mortality, respectively. This is of great interest because CVD remains the most common cause of death worldwide, accounting for 45% of all deaths in Europe (Townsend et al. 2016) and is estimated to cost healthcare services £15.7 billion in the UK alone (Luengo-Fernandez et al. 2006 ). Our findings are of a similar magnitude to a recent meta-analysis that found that berry intake was associated with a significant reduction in all-cause mortality (RR ¼ 0.92, 95% CI: 0.88, 0.97; I 2 ¼ 8.0, P h ¼ 0.34) (Aune et al. 2017) . Moreover, Guo and colleagues (2016) previously reported that risk of type II diabetes was reduced (5%) by increasing anthocyanin intake (7.5 mg/day; RR ¼ 0.95; 95% CI: 0.93, 0.98) and berry intake (17 g/day; RR ¼ 0.95; 95% CI: 0.91, 0.99), suggesting these compounds have a number of health benefits.
Conversely, there was no relationship between intake of anthocyanins and risk of stroke. Further stratification by types of stroke because of possible differences in underlying mechanisms (Figure 4 ) revealed there was no relationship between the intake of these compounds and cerebral infarction, ischemic or hemorrhagic strokes. The reasons for the different risk estimates between anthocyanin intake and CHD versus stroke remains unknown, but might be because 1) anthocyanins do not circulate the brain in large enough doses to elicit neurovascular protection, or 2) the cerebrovasculature is more susceptible to atherosclerosis because of the smaller vessel diameters (Mursu et al. 2008) . Our findings are consistent with a recent meta-analysis that reported highest berry intake was not associated with reduced risk of stroke (RR ¼ 0.98, 95% CI: 0.86, 1.12) (Aune et al. 2017 ). The majority of included stroke studies in the current metaanalysis had berries as the exposure (Table 2 ; supplemental).
Berries are a major source of anthocyanins, but these compounds are not uniformly distributed between these and other sources (Clifford, 2000; Horbowicz et al. 2008) . In a subgroup-analysis we found more prominent relationships between anthocyanidins and reduced risk of CHD (16%) and CVD mortality (8%). Interestingly, because the included studies reported sources other than berries, such as red wine and cherries to significantly contribute to overall anthocyanin intake (Ponzo et al. 2015; Tresserra-Rimbau et al. 2014) , perhaps the specific anthocyanins needs more careful consideration.
A strength of this meta-analysis was the inclusion of multivariate-adjusted risk models that adjusted for important confounding variables. However, a limitation of the included studies is that intake of anthocyanins is positively correlated to fruit and vegetable intake and the beneficial nutrients associated with these, such as other flavonoids, vitamins, carotenoids and fiber (Zamora-Ros et al. 2013) . Thus, because of multicollinearity, and because only some studies adjusted for some of these as covariates (Table 1) , it is not possible to isolate whether the observed reduction in risk estimates is solely in response to intake of dietary anthocyanidins and not other bioactive compounds. We also found varying risk estimates for study locations; for example, reduced risk of CHD and CVD mortality only remained significant in the USA (Table 2 ; supplemental). It is plausible that this is attributable to differing dietary patterns and inclusion of a diet richer in anthocyanidins (Wu et al. 2006; Zamora-Ros et al. 2011 ) and altered the bioavailabity of these compounds in vivo, especially in relation to interactions between diet and host microbiome (D'Archivio et al. 2010) . It should also be acknowledged that other bioactive compounds, not just anthocyanidins, are likely to have synergistic interactions (Keane et al. 2016; Kirakosyan et al. 2010 ) and might not be as beneficial in isolation. Nonetheless, recent in vitro and human studies of anthocyanins and their relevant metabolites suggests that these compounds are responsible for some degree of cardioprotection (Fairlie-Jones et al. 2017; Reis et al. 2016) . Although teleologically intuitive, this concept and the results of this metaanalysis should be interpreted cautiously given that previous studies have failed to demonstrate reduced risk of chronic diseases with antioxidant supplementation (Bjelakovic et al. 2012) . Therefore, future randomized controlled trials should determine the longitudinal effects of anthocyanin supplementation on CHD and CVD risk factors to support the findings of the current meta-analysis.
In summary, this systematic review and meta-analysis provides further support that anthocyanins, specifically anthocyanidins, reduce the risk of CHD and CVD mortality, which from a public health perspective might help reduce the associated socioeconomic burdens. However, there was no relationship between the intake of these compounds and reduced risk of MI, stroke or total CVD; moreover, whether particular groups of anthocyanin-containing foods, such as berries, seem to be more beneficial than other fruits or vegetables remains to be established. Until more precise conclusions can be made, we recommend that dietary intake should include anthocyanidin-rich sources adjunct a varied diet of fruit and vegetables rich in other bioactive compounds. Further longitudinal randomized controlled trials determining the effect of anthocyanin intake on cardiovascular risk factors are needed to support the findings of the current meta-analysis.
Abbreviations BMI body mass index CHD coronary heart disease CVD cardiovascular disease HR hazard ratio FFQ food frequency questionnaire MI myocardial infarction MOOSE meta-analysis of observational studies in epidemiology PRISMA preferred reporting items for systematic reviews and meta-analysis RR relative risk SE standard error ORCID Glyn Howatson https://orcid.org/0000-0001-8494-2043
